Merit Medical Systems, Inc. (MMSI)
| Market Cap | 5.20B -1.2% |
| Revenue (ttm) | 1.58B +10.2% |
| Net Income | 145.56M +22.2% |
| EPS | 2.43 +23.2% |
| Shares Out | 59.71M |
| PE Ratio | 35.80 |
| Forward PE | 19.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 395,502 |
| Open | 87.53 |
| Previous Close | 86.36 |
| Day's Range | 86.03 - 87.83 |
| 52-Week Range | 59.74 - 94.75 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 101.45 (+16.58%) |
| Earnings Date | Oct 29, 2026 |
About MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology produc... [Read more]
Financial Performance
In 2025, Merit Medical Systems's revenue was $1.52 billion, an increase of 11.75% compared to the previous year's $1.36 billion. Earnings were $128.49 million, an increase of 6.76%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MMSI stock is "Buy." The 12-month stock price target is $101.45, which is an increase of 16.58% from the latest price.
News
Merit Medical Systems Transcript: Wells Fargo 21st Annual Healthcare Conference
Leadership transition has been smooth, with robust Q2 growth and a strategic plan nearing completion. Financial guidance remains conservative, while product and regional strategies focus on evolving platforms, expanding oncology, and leaning into China.
Merit Medical to Participate in Upcoming Investors Conferences in September
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate...
Merit Medical Announces Global Operations Leadership Transition
SOUTH JORDAN, Utah, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer of healthcare technology, today announced that Sheri Lewis has agreed to...
Merit Medical price target raised to $97 from $92 at BofA
BofA raised the firm’s price target on Merit Medical (MMSI) to $97 from $92 and keeps a Neutral rating on the shares after hosting CFO Raul Parra for a virtual…
Merit Medical Systems Transcript: Bank of America SMID Cap Virtual Conference
The event highlighted ongoing strategic planning, a new reporting structure, and strong financial performance, including margin expansion and raised revenue guidance. Growth is driven by both Foundational and Therapeutic platforms, with disciplined M&A and a focus on deepening existing market presence.
Merit Medical Systems Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is on track to meet its current strategic goals and is developing a new three-year plan, with a focus on portfolio optimization, operational efficiency, and targeted M&A. Recent product launches and acquisitions are expanding market reach, while leadership emphasizes execution and adaptability.
Merit Medical to Participate in Upcoming Investors Conferences in August
SOUTH JORDAN, Utah, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management will participate in the upco...
Merit Medical price target raised to $94 from $85 at Canaccord
Canaccord raised the firm’s price target on Merit Medical (MMSI) to $94 from $85 and keeps a Buy rating on the shares. The firm said they reported an all-around, strong…
Merit Medical price target raised to $114 from $107 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Merit Medical (MMSI) to $114 from $107 and keeps an Outperform rating on the shares. The firm views the company’s…
Merit Medical price target raised to $100 from $83 at Raymond James
Raymond James raised the firm’s price target on Merit Medical (MMSI) to $100 from $83 and keeps an Outperform rating on the shares. Merit Medical’s Q2 results showed a sharp…
Merit Medical price target raised to $105 from $100 at BTIG
BTIG analyst Sam Eiber raised the firm’s price target on Merit Medical (MMSI) to $105 from $100 and keeps a Buy rating on the shares. The company delivered a standout…
Merit Medical price target raised to $95 from $77 at JPMorgan
JPMorgan raised the firm’s price target on Merit Medical (MMSI) to $95 from $77 and keeps an Overweight rating on the shares.
Merit Medical price target raised to $101 from $90 at Needham
Needham analyst Mike Matson raised the firm’s price target on Merit Medical (MMSI) to $101 from $90 and keeps a Buy rating on the shares. The company Q2 revenue and…
Merit Medical price target raised to $106 from $96 at Piper Sandler
Piper Sandler raised the firm’s price target on Merit Medical (MMSI) to $106 from $96 and keeps an Overweight rating on the shares following quarterly results. The firm notes shares…
Merit Medical price target raised to $98 from $89 at Baird
Baird raised the firm’s price target on Merit Medical (MMSI) to $98 from $89 and keeps an Outperform rating on the shares. The firm updated its model following beat and…
Merit Medical Systems Earnings Call Transcript: Q2 2026
Q2 2026 delivered 10% GAAP and 9% organic revenue growth, with strong performance across product lines and geographies. Profitability exceeded expectations, guidance was raised for the year, and recent acquisitions outperformed. Tariff volatility and seasonality remain key considerations.
Merit Medical Systems Earnings release: Q2 2026
Merit Medical Systems released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Merit Medical Systems Slides: Q2 2026
Merit Medical Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Merit Medical Systems Quarterly report: Q2 2026
Merit Medical Systems has published its Q2 2026 quarterly earnings report on July 30, 2026.
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
Financial Highlights† Reported revenue of $418.8 million, up 10% Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively GAAP operating margin of 14.4%, compar...
Merit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026
SOUTH JORDAN, Utah, July 02, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results f...
Merit Medical Systems Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is executing a strategic re-segmentation and CEO transition, improving reporting clarity and platform accountability. Growth is driven by volume, new products, and targeted acquisitions, with foundational and therapeutic segments performing in line with multi-year targets. Financial guidance remains realistic, with ongoing margin expansion and a strong focus on portfolio optimization.
Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders ...
Merit Medical Systems Transcript: AGM 2026
Shareholders approved all proposals, including director elections and compensation plans, and welcomed a new CEO and director. The company reported record financial results, continued innovation, and outlined ongoing strategic growth initiatives.
Merit Medical Systems Transcript: Bank of America Global Healthcare Conference 2026
Revised summary: Leadership emphasized a shift to platform-based management, aligning reporting with operations and focusing on scaling through people, process, and innovation. Growth is driven by foundational and therapeutic platforms, with acquisitions expanding offerings. Margin expansion and diversified growth remain priorities, with ongoing strategic planning and prudent M&A.